Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation
Latest Information Update: 07 Mar 2024
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Bronchiolitis obliterans
- Focus Therapeutic Use
- Acronyms RESPPEDOPS
- Sponsors GSK
- 27 Feb 2024 Status changed from recruiting to discontinued due to insufficient enrollment.
- 20 Oct 2020 New trial record